博腾股份公告，全资子公司重庆博腾药业有限公司近日获得欧盟质量受权人签发的符合性声明，顺利通 过欧盟QP审计。 ...

关于全资子公司通过欧盟 QP 审计的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）全资子公司重庆博腾 药业有限公司（以下简称"博腾药业"）于近日获得欧盟质量受权人（Qualified Person, QP）签发的符合性声明，顺利通过欧盟 QP 审计。 本次审计依据 EU GMP Guidelines EudraLex Volume 4、EU Clinical Trial Regulation（536/2014）及 GMP for IMP 指导原则，审计范围涵盖了公司重庆制 剂生产基地注射剂、口服固体制剂及非无菌半固体制剂业务的质量管理、生产管 理、厂房设备设施、物料系统、包装与标签系统等方面。本次顺利通过 QP 审计， 标志着博腾药业质量管理体系已达到欧盟 GMP 标准，能够为全球客户提供符合 国际标准的制剂定制研发生产服务。 股票代码：300363 股票简称：博腾股份 公告编号：2025-060 号 重庆博腾制药科技股份有限公司 2025 年 12 月 29 日 本次通过欧盟 QP 审计不会对公司当前业绩 ...

诺纳生物首席执行官洪涤博士表示，作为一家以全人源抗体技术为核心的国际化生物技术公司，诺纳生 物始终致力于通过源头技术平台与一体化研发解决方案赋能全球创新。此次与博腾达成战略合作，将进 一步强化公司在复杂抗体药物全生命周期的综合能力。借助博腾在CMC开发、全球合规及商业化生产 领域的深厚积淀，诺纳生物能够更高效地将领先的抗体发现技术转化为具备全球竞争力的临床候选分子 与商业化产品，实现从"源头创新"到"全球交付"的完整价值链闭环，从而为客户与合作伙伴提供更具确 定性、更可持续的赋能价值。 12月22日，全人源抗体技术领军企业诺纳生物与全球领先的CDMO企业博腾正式达成深度战略合作。双 方将聚焦双抗、多抗等复杂抗体类新型治疗方式的全生命周期研发生产，通过"创新技术平台+产业化 落地能力"的精准协同，破解新型抗体药物工艺开发难、合规要求高、成本挑战大、转化周期长的行业 痛点，加速创新疗法从实验室走向临床及市场，为全球患者提供更具可及性的突破性治疗方案。 博腾股份（300363）董事长兼总经理居年丰表示，博腾深耕CDMO领域二十年，构建了一站式、全类别 CMC技术平台与全球合规体系，积累了与全球制药企业和生物技术公司 ...

Core Viewpoint - Increasing number of pharmaceutical companies are investing in funds to indirectly participate in promising startups and emerging technologies, enhancing their innovation and competitiveness [1][6]. Group 1: Recent Fund Investments - On December 17, 2023, Furuya Medical and Boteng Co. announced their plans to invest in funds, with Furuya Medical committing up to 93 million yuan in a private equity fund [2]. - Boteng Co. plans to acquire a portion of shares in the Yifeng Yunding Venture Capital Partnership for a nominal fee, committing to a capital contribution of 20 million yuan [2]. Group 2: Industry Trends - Several pharmaceutical companies, including Huilong Pharmaceutical, Yingke Medical, and Pianzaihuang, have also made fund investments this year, indicating a trend in the industry [4]. - Pianzaihuang has made multiple fund investments, including a 200 million yuan commitment to the Zhaoying Fund, representing 20% of its target fundraising [4][5]. Group 3: Strategic Implications - Investment in funds allows companies to access cutting-edge technologies and market dynamics, potentially leading to future business expansions and technology introductions [3][6]. - Engaging in fund investments can enhance resource sharing and collaboration with other companies and research institutions, fostering innovation and competitive advantages [5][6]. Group 4: Focus Areas of Investment - The funds targeted by these pharmaceutical companies primarily focus on biomedicine and related fields, with Boteng Co.'s investments directed towards innovative drugs and high-end medical devices [7][8]. - Furuya Medical's proposed fund, Chengde Fund, emphasizes strategic emerging industries, particularly in medical technology and digital economy, with at least 50% of investments in biomedicine and health technology [7][8]. Group 5: Structural Changes in the Industry - The trend of pharmaceutical companies investing in funds reflects a structural shift from a "product-driven" approach to a "dual-driven" model combining products and investments, indicating a deep integration of industry and capital [8].

Core Viewpoint - Increasing number of pharmaceutical companies are investing in funds to enhance innovation and gain access to emerging technologies and startups, reflecting a strategic shift in the industry towards capital operations for additional revenue and risk diversification [1][7][10] Group 1: Recent Fund Investments - On December 17, 2023, Furuya Medical and Boteng Co. announced their plans to invest in funds, with Furuya Medical committing up to 93 million yuan in a private equity fund focused on high-tech innovation [4] - Boteng Co. plans to acquire a portion of the Yifeng Yunding Fund for 1 yuan, with a commitment to contribute 20 million yuan, targeting investments in the healthcare sector [4][9] Group 2: Industry Trends - Multiple pharmaceutical companies, including Huilong Pharmaceutical, Yingke Medical, and Pianzaihuang, have made similar fund investments this year, indicating a growing trend in the industry [6] - Huilong Pharmaceutical's recent investment focuses on late-stage clinical projects with clear commercial potential, while Pianzaihuang has engaged in several fund investments, emphasizing a strategic approach to enhance core competitiveness [6][10] Group 3: Strategic Benefits - Investing in funds allows pharmaceutical companies to access cutting-edge technologies and market dynamics, potentially leading to future business expansions and technology introductions [5][8] - The strategy also facilitates partnerships within the industry, enhancing resource sharing and competitive advantages [5][8] Group 4: Investment Focus - The funds being invested in primarily target the biopharmaceutical sector, with a focus on innovative drugs, high-end medical devices, and health technology [9][10] - Furuya Medical's targeted fund emphasizes international cooperation and strategic emerging industries, with at least 50% of investments directed towards biopharmaceuticals and health technology [9][10]

Group 1 - CICC is planning to absorb and merge Dongxing Securities and Xinda Securities through a share swap, with trading resuming on December 18, 2025 [1] - Victory Energy's major shareholder plans to transfer 29.99% of its shares to Qiteng Robotics, with no plans for asset restructuring in the next 12 months [2] - China Metallurgical Group intends to repurchase A-shares worth 1 to 2 billion yuan at a price not exceeding 4.9 yuan per share [3] Group 2 - Boten Co. plans to acquire part of the Yifeng Yunding Fund for 1 yuan, with a commitment to fulfill a 20 million yuan capital contribution [4] - Tongyou Technology has initiated a 50 million yuan accounts receivable factoring business [5] - Gaode Infrared has received approval to issue debt financing tools totaling up to 3 billion yuan [6] Group 3 - Zhengyu Industrial's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] - China CRRC signed contracts totaling approximately 53.31 billion yuan, accounting for 21.6% of its projected 2024 revenue [9] - High Energy Environment's director increased his stake by purchasing 56,100 shares [10] Group 4 - Shantou Technology received approval from the CSRC for a convertible bond issuance [11] - Puyang Co. plans to use up to 900 million yuan of idle funds for entrusted wealth management [12] - Huibai New Materials has been awarded a government subsidy of 3.8 million yuan, with the first installment of 2.12 million yuan already received [13] Group 5 - Jiayuan Technology's shareholders plan to transfer 2.51% of the company's shares through a pricing inquiry [14] - Lingpai Technology's subsidiary terminated a 125 million yuan procurement contract due to market changes [15] - Juguang Technology intends to use up to 200 million yuan of idle funds for cash management [16] Group 6 - Zhongwen Media's subsidiary terminated a 200 million yuan private equity fund subscription due to market changes [17] - Zhifei Biological's modified vaccine for monkeypox has received clinical trial acceptance [19] - GeKowei's subsidiary received a government subsidy of 60 million yuan, accounting for 32.12% of the company's audited net profit [20] Group 7 - Wantai Biological's application for a clinical trial of a respiratory syncytial virus vaccine has been accepted [21] - Haitai Technology plans to increase capital in its Thai joint venture from 500,000 to 3 million Thai baht [22] - Shanghai Airport signed contracts for the transfer of duty-free store operating rights [23] Group 8 - Del Shares received approval to issue shares for the acquisition of 100% of Aizhuo Intelligent [24] - Novozymes' products have obtained EU CE IVDR certification [25] - Shibai Testing's chairman's assistant plans to increase shareholding by 8 to 12 million yuan [26] Group 9 - Huitian New Materials plans to invest approximately 97.68 million yuan in a lithium battery anode glue project [27] - Pudong Construction's subsidiaries won contracts totaling 1.649 billion yuan [29] - Acolyte's subsidiary has entered trial production for a special high-temperature resistant resin project [30] Group 10 - Pingzhi Information's subsidiary signed a 38.25 million yuan computing power service contract [31] - Tianma Technology is required to pay 5.3625 million yuan in taxes and penalties [32] - Yahon Pharmaceutical's clinical trial application for GLX002 has been approved [34]

Group 1 - The company plans to acquire part of the shares of Shenzhen Yifeng Yunding Venture Capital Partnership (Limited Partnership) from Chen Yanxi for a consideration of 1 yuan [1] - Upon completion of the acquisition, the company will fulfill its obligation to contribute 20 million yuan as per the partnership agreement [1] - The Yifeng Yunding Fund specializes in investments in Hangzhou Yifeng Runjun Venture Capital Partnership (Limited Partnership), allowing the company to achieve indirect investment in the Yifeng Runjun Fund through the Yifeng Yunding Fund [1]

深圳市倚锋投资管理企业(有限合伙)是国内最早一批生物医药专业投资机构，专注于全球生物医药投 资。本次投资有助于公司借助专业投资机构的优质资源，帮助公司业务和客户导入及战略资源引入。倚 锋云鼎基金专项投资于倚锋润君基金，倚锋润君基金主要投资于医疗健康板块的原创新药、高端医疗器 械、生物科技及国内外相关领域的优质标的企业，所投资项目可能与公司存在业务合作等协同关系。 智通财经APP讯，博腾股份(300363.SZ)发布公告，公司拟以1元对价受让陈彦希持有的深圳市倚锋云鼎 创业投资合伙企业(有限合伙)(简称"倚锋云鼎基金")部分份额，受让完成后，公司将按照《合伙协议》 的约定履行2000万元认缴份额的实缴出资义务。倚锋云鼎基金专项投资于杭州倚锋润君创业投资合伙企 业(有限合伙)(简称"倚锋润君基金")，公司将通过投资倚锋云鼎基金，实现对倚锋润君基金的间接投 资。 ...

智通财经APP讯，博腾股份(300363.SZ)发布公告，公司拟以1元对价受让陈彦希持有的深圳市倚锋云鼎 创业投资合伙企业(有限合伙)(简称"倚锋云鼎基金")部分份额，受让完成后，公司将按照《合伙协议》 的约定履行2000万元认缴份额的实缴出资义务。倚锋云鼎基金专项投资于杭州倚锋润君创业投资合伙企 业(有限合伙)(简称"倚锋润君基金")，公司将通过投资倚锋云鼎基金，实现对倚锋润君基金的间接投 资。 深圳市倚锋投资管理企业(有限合伙)是国内最早一批生物医药专业投资机构，专注于全球生物医药投 资。本次投资有助于公司借助专业投资机构的优质资源，帮助公司业务和客户导入及战略资源引入。倚 锋云鼎基金专项投资于倚锋润君基金，倚锋润君基金主要投资于医疗健康板块的原创新药、高端医疗器 械、生物科技及国内外相关领域的优质标的企业，所投资项目可能与公司存在业务合作等协同关系。 ...

Core Viewpoint - The company, Boten Co., Ltd. (博腾股份), plans to acquire a portion of shares from Chen Yanxi in the Shenzhen Yifeng Yunding Venture Capital Partnership (Limited Partnership) for a nominal price of 1 yuan, committing to a capital contribution of 20 million yuan as per the partnership agreement [1] Group 1 - The acquisition will allow the company to indirectly invest in the Hangzhou Yifeng Runjun Venture Capital Partnership (Limited Partnership) through the Yifeng Yunding Fund [1] - The Yifeng Runjun Fund primarily focuses on investments in the healthcare sector, including innovative drugs, high-end medical devices, biotechnology, and quality enterprises in related fields both domestically and internationally [1]